Carcinoembryonic antigen (CEA), an oncofetal antigen, is an extensively used disease relapse marker [3]; however, the utility of serial CEA testing remains uncertain: in 30%–40% of all CRC recurrences, the serum CEA shows unmeasurable elevations [4]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.